Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-0: First-line osimertinib in elderly EGFR-mutant NSCLC
jRCTs071180007Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by AstraZeneca. Primary endpoint: 1-year progression-free survival rate. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCTs071180007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180007.